FDA considers classification of ECT.
Publication
, Journal Article
Lisanby, SH; Pallanti, S; Schlaepfer, TE
Published in: CNS Spectr
December 2009
Duke Scholars
Published In
CNS Spectr
DOI
ISSN
1092-8529
Publication Date
December 2009
Volume
14
Issue
12
Start / End Page
668 / 670
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Psychiatry
- Humans
- Electroconvulsive Therapy
- 5202 Biological psychology
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lisanby, S. H., Pallanti, S., & Schlaepfer, T. E. (2009). FDA considers classification of ECT. CNS Spectr, 14(12), 668–670. https://doi.org/10.1017/s1092852900023920
Lisanby, S. H., Stefano Pallanti, and Thomas E. Schlaepfer. “FDA considers classification of ECT.” CNS Spectr 14, no. 12 (December 2009): 668–70. https://doi.org/10.1017/s1092852900023920.
Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS Spectr. 2009 Dec;14(12):668–70.
Lisanby, S. H., et al. “FDA considers classification of ECT.” CNS Spectr, vol. 14, no. 12, Dec. 2009, pp. 668–70. Pubmed, doi:10.1017/s1092852900023920.
Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS Spectr. 2009 Dec;14(12):668–670.
Published In
CNS Spectr
DOI
ISSN
1092-8529
Publication Date
December 2009
Volume
14
Issue
12
Start / End Page
668 / 670
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Psychiatry
- Humans
- Electroconvulsive Therapy
- 5202 Biological psychology
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences
- 1103 Clinical Sciences